-$0.20 EPS Expected for POINT Biopharma Global Inc. (NASDAQ:PNT) This Quarter

Equities research analysts expect POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating) to report earnings of ($0.20) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for POINT Biopharma Global’s earnings, with estimates ranging from ($0.27) to ($0.16). The firm is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that POINT Biopharma Global will report full year earnings of ($0.89) per share for the current fiscal year, with EPS estimates ranging from ($1.16) to ($0.72). For the next financial year, analysts anticipate that the company will post earnings of ($0.82) per share, with EPS estimates ranging from ($1.08) to ($0.52). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow POINT Biopharma Global.

POINT Biopharma Global (NASDAQ:PNT – Get Rating) last released its quarterly earnings data on Friday, March 25th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.10).

Separately, Zacks Investment Research cut POINT Biopharma Global from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, POINT Biopharma Global currently has a consensus rating of “Hold” and an average price target of $27.20.

Shares of NASDAQ PNT traded down $0.46 during trading on Friday, hitting $8.51. The company had a trading volume of 241,918 shares, compared to its average volume of 240,051. The stock has a 50 day simple moving average of $7.39 and a 200 day simple moving average of $7.15. POINT Biopharma Global has a 12 month low of $4.25 and a 12 month high of $11.72.

Institutional investors have recently made changes to their positions in the business. Morgan Stanley purchased a new position in POINT Biopharma Global in the third quarter worth approximately $27,000. Cubist Systematic Strategies LLC purchased a new position in shares of POINT Biopharma Global during the third quarter worth $28,000. Penserra Capital Management LLC purchased a new position in shares of POINT Biopharma Global during the fourth quarter worth $25,000. Marshall Wace LLP acquired a new stake in shares of POINT Biopharma Global in the fourth quarter valued at $27,000. Finally, Legal & General Group Plc acquired a new stake in shares of POINT Biopharma Global in the fourth quarter valued at $38,000. 35.95% of the stock is owned by institutional investors and hedge funds.

About POINT Biopharma Global (Get Rating)

POINT Biopharma Global Inc, a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.

Featured Stories